RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 1,330 Shares

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 1,330 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $46.13, for a total value of $61,352.90. Following the completion of the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $1,948,807.98. This trade represents a 3.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total value of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total transaction of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total transaction of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.68, for a total transaction of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total transaction of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total transaction of $148,831.00.

RxSight Trading Up 3.1 %

RXST stock traded up $1.38 during trading on Friday, hitting $45.54. The company had a trading volume of 118,219 shares, compared to its average volume of 487,930. RxSight, Inc. has a fifty-two week low of $27.07 and a fifty-two week high of $66.54. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of -53.20 and a beta of 1.19. The business has a 50 day moving average of $50.48 and a 200 day moving average of $53.33.

Analysts Set New Price Targets

A number of equities research analysts recently commented on RXST shares. Stifel Nicolaus decreased their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Oppenheimer lowered their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Jefferies Financial Group began coverage on RxSight in a research report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price on the stock. Finally, Wells Fargo & Company reduced their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, RxSight presently has a consensus rating of “Buy” and an average target price of $61.63.

Institutional Investors Weigh In On RxSight

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Oppenheimer & Co. Inc. bought a new stake in shares of RxSight in the first quarter valued at about $364,000. Swiss National Bank boosted its stake in RxSight by 16.2% in the 1st quarter. Swiss National Bank now owns 53,100 shares of the company’s stock worth $2,739,000 after purchasing an additional 7,400 shares during the period. ProShare Advisors LLC acquired a new stake in shares of RxSight in the 1st quarter valued at approximately $263,000. Entropy Technologies LP grew its position in shares of RxSight by 67.2% in the 1st quarter. Entropy Technologies LP now owns 13,437 shares of the company’s stock valued at $693,000 after acquiring an additional 5,399 shares during the period. Finally, M&G Plc acquired a new stake in shares of RxSight in the first quarter valued at approximately $7,354,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.